000			05645nam a22004813i 4500
001			EBC3018941
003			MiAaPQ
005			20240729124109.0
006			m o d |
007			cr cnu||||||||
008			240724s2009 xx o ||||0 eng d
020			_a9781612098678 _q(electronic bk.)
020			_z9781607419754
035			_a(MiAaPQ)EBC3018941
035			_a(Au-PeEL)EBL3018941
035			_a(CaPaEBR)ebr10662747
035			_a(OCoLC)847090008
040			_aMiAaPQ _beng _erda _epn _cMiAaPQ _dMiAaPQ
050		4	_aRC903 -- .C25 2009eb
082	0		_a616.6/1061
100	1		_aRobles, Nicolás Roberto.
245	1	0	_aCalcium Channel Blockers and Renal Disease.
250			_a1st ed.
264		1	_aNew York : _bNova Science Publishers, Incorporated, _c2009.
264		4	_c©2009.
300			_a1 online resource (195 pages)
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
490	1		_aCerebrovascular Research and Disorders
505	0		_aIntro -- CALCIUM CHANNEL BLOCKERSAND RENAL DISEASE -- CALCIUM CHANNEL BLOCKERS AND RENAL DISEASE -- Contents -- Preface -- List of Authors -- Pharmacology of CalciumAntagonists -- Mechanisms of Action -- Differences among Calcium-Antagonists -- Clinical Pharmacology -- Pharmacokinetics -- Pharmacodynamics -- Tolerance -- Sympathetic Activation -- Ankle edema -- Other Untoward Effects -- Therapeutic Uses -- Hypertension -- Angina Pectoris -- Supraventricular Arrhythmias -- Subarachnoid Hemorrhage -- Myocardial Infarction -- Risk of Cancer -- Drug Interactions -- Special Considerations -- Older Patients -- Metabolic Syndrome -- Patients with Congestive Heart Failure -- Overdose of CCBs -- References -- Calcium Antagonists and SystemicHypertension -- Abstract -- Calcium Channel Blockers:The Findings of Clinical Trials -- Calcium Channel Blockers and Target OrganDisease -- 1. Calcium Channel Blockers and Arteriosclerosis -- 2. Use of Calcium Channel Antagonists in Coronary Disease(CHD) -- 3. Effects on Cerebrovascular Disease: Clinical Trials -- 4. Meta-Analysis on Cerebrovascular Outcomes -- Conclusions -- References -- Effects of Calcium Antagonists inRenal Hemodynamics -- Abstract -- 1. Ca2+ Channels and Vasoconstriction -- 1.1. Diversity of Ca2+ Channels -- 1.2. The Traditional Vision: The Role of L-Type Ca2+ Channels -- 1.3. The Emerging Evidences for Other Types of Ca2+ Channels -- 2. The Use of CCBs for BP Control inHypertension -- 2.1. The Principle of Ca2+ Antagonism -- 2.2. The Mechanism of "Ca2+ Antagonism" in Hypertension -- 3. Effects of CCBs on Microcirculation andRenal Hemodynamics -- 3.1. CCBs and Renal Protection -- 3.2. Mechanisms for Beneficial Renal Effects of New CCBs -- 3.2.1. DHP-Insensitive Ca2+ Channels in the Microcirculation andKidneys -- 3.2.2. DHP-Insensitive Ca2+ Channels in the Sympathetic Nerves.
505	8		_a3.2.3. New DHPs Cause New Effects on Renal Function -- 3.2.4. Limitations and Pertaining Questions -- Conclusion - Prospects -- References -- The Non-Hemodynamic Effects ofCalcium Channel Blockers on theKidney -- 1. Introduction -- 2. Antioxidant Effects -- 2.1. End-Stage Renal Disease -- 2.2. Diabetes -- 2.3. Effects of Associations -- 3. Effect on the Proliferation of MesangialCells -- 4. Effect on Fibrosis and Apoptosis -- 5. Other Effects -- Summary -- References -- Renoprotective Effect of CalciumAntagonists in SystemicHypertension -- Introduction -- Overview of Relevant Trials Regarding CCBsand Renal Protection in HypertensivePatients -- CCBs and Renal Protection in the Presenceof Preserved Renal Function -- Blood Pressure Control andNephroprotection in Patients withEstablished Chronic Kidney Disease -- Conclusions -- References -- Calcium Antagonists and RenalDisease -- Introduction -- Effects Calcium Channel Blockers on RenalHemodynamics -- Renoprotective Effect of CalciumAntagonists in Animals -- Effects on the Progression of Renal Injuryin Humans -- Calcium Antagonists versus Renin-Angiotensin Axis Blocking Drugs -- Calcium Antagonists versus Diuretics -- Comparison between Calcium-Antagonists -- New Calcium Antagonists -- Conclusion -- References -- Renal Ischaemia and CalciumChannel Blockers (CCBs) -- Introduction -- Chronic Renal Ischaemia -- Definition -- Pathogenic Mechanisms -- Epidemiology -- Morphology -- Clinical Presentation -- Calcium Channel Blockers and RID -- Contrast-Induced Nephropathy AND CCBs -- Risk Factors OF CIN -- Prevention of Radiocontrast Nephropathy -- References -- Calcium Antagonist after KidneyTransplantation -- Drug Treatment in Post-TransplantationArterial Hypertension -- References -- Non Dihydropyridinic CalciumAntagonists and Renal Disease.
505	8		_aNondihydropiridine Calcium ChannelBlockers vs Other Antihypertensive Agents -- Combination Therapy -- Conclusions -- References -- Index.
588			_aDescription based on publisher supplied metadata and other sources.
590			_aElectronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.
650		0	_aKidneys -- Diseases -- Chemotherapy.
650		0	_aCalcium -- Antagonists.
655		4	_aElectronic books.
776	0	8	_iPrint version: _aRobles, Nicolás Roberto _tCalcium Channel Blockers and Renal Disease _dNew York : Nova Science Publishers, Incorporated,c2009 _z9781607419754
797	2		_aProQuest (Firm)
830		0	_aCerebrovascular Research and Disorders
856	4	0	_uhttps://ebookcentral.proquest.com/lib/orpp/detail.action?docID=3018941 _zClick to View
999			_c59959 _d59959